Schurch Brigitte, Denys Pierre, Kozma Chris M, Reese Pat Ray, Slaton Terra, Barron Rich
Spinal Cord Injury Center, University Hospital Balgrist, Zurich, Switzerland.
Arch Phys Med Rehabil. 2007 May;88(5):646-52. doi: 10.1016/j.apmr.2007.02.009.
To assess the reliability, validity, responsiveness, and minimally important difference (MID) of the Incontinence Quality of Life (I-QOL) questionnaire in patients with urinary incontinence due to neurogenic detrusor overactivity.
Randomized, double-blind, multicenter, placebo-controlled study.
Eight centers across Belgium, France, and Switzerland.
Patients with urinary incontinence due to neurogenic detrusor overactivity inadequately managed on oral anticholinergics. Fifty-nine patients (spinal cord injury, n=53; multiple sclerosis, n=6) were enrolled.
Single dose of botulinum toxin type A (Botox) (200 or 300 U) or placebo.
I-QOL questionnaire completed at screening and over a 24-week post-treatment period.
The Cronbach alpha ranged from .79 to .93, indicating that I-QOL is a reliable measure of QOL in neurogenic urinary incontinence patients. No item had more than 5.1% missing or out of range values. With the exception of 2 items, questions showed acceptable item-scale correlation and scaling success results varied by domain. Post-treatment correlations indicated acceptable construct validity. The I-QOL was responsive to improvements in symptoms. MID values ranged from 4 to 11 points.
Results suggest that I-QOL is a reliable, valid, and responsive measure of incontinence-related QOL in neurogenic patients.
评估尿失禁生活质量（I-QOL）问卷在神经源性逼尿肌过度活动所致尿失禁患者中的信度、效度、反应度和最小重要差异（MID）。
随机、双盲、多中心、安慰剂对照研究。
比利时、法国和瑞士的8个中心。
口服抗胆碱能药物治疗效果不佳的神经源性逼尿肌过度活动所致尿失禁患者。共纳入59例患者（脊髓损伤，n = 53；多发性硬化症，n = 6）。
单剂量A型肉毒毒素（保妥适）（200或300单位）或安慰剂。
在筛查时以及治疗后24周期间完成I-QOL问卷。
克朗巴哈系数在0.79至0.93之间，表明I-QOL是神经源性尿失禁患者生活质量的可靠测量指标。没有任何一项的缺失值或超出范围的值超过5.1%。除2项外，各问题显示出可接受的项目-量表相关性，且量表成功结果因领域而异。治疗后的相关性表明具有可接受的结构效度。I-QOL对症状改善有反应。MID值范围为4至11分。
结果表明，I-QOL是神经源性患者尿失禁相关生活质量的可靠、有效且有反应度的测量指标。
